Get the Daily Brief
Latest Biotech News
Sequencing speed and code‑decoding: sub‑4‑hour WGS and SDR‑seq map hidden variants
Broad Clinical Labs, in collaboration with Roche and Boston Children’s, reported an ultra‑rapid whole‑genome sequencing workflow using Roche’s SBX technology that reduced sample‑to‑variant...
Megarounds return: private financings surge as biotech rebounds
A wave of nine‑figure private financings signaled renewed investor appetite for late‑stage and platform biotechs, with multiple companies disclosing large rounds that pushed weekly totals higher....
ESMO ADC showdown: AstraZeneca and Gilead square off in TNBC
AstraZeneca and Gilead presented head-to-head Phase 3 data at ESMO showing competing antibody-drug conjugates (ADCs) for metastatic triple-negative breast cancer (TNBC), creating a direct choice...
New combo cuts mortality 40% in recurrent prostate cancer
A late‑stage clinical trial reported a new drug combination that reduced mortality risk by roughly 40% in men with high‑risk biochemically recurrent prostate cancer after prior surgery or...
Tubulis: next‑gen ADC posts 59% ORR — investors back with $361M
Tubulis unveiled first‑in‑human data for its NaPi2b‑targeting ADC TUB‑040 showing a 59% overall response rate (ORR) across dose cohorts in heavily pretreated patients, and reported a wide...
Grail’s Galleri: improved accuracy as FDA filing approaches
Grail released new PATHFINDER2 data from a 36,000‑participant U.S. study showing the Galleri multi‑cancer screening test detected 40.4% of cancers in participants followed for a year, with...
Broad and Roche set new sub‑4‑hour whole‑genome sequencing benchmark
Broad Clinical Labs, in collaboration with Roche and Boston Children’s Hospital, reported an optimized sequencing workflow using Roche’s Sequencing‑by‑Expansion (SBX) prototype that reduced...
Sophia Genetics launches Digital Twins to model cancer trajectories
Sophia Genetics unveiled a new research‑use Digital Twins module within its Sophia DDM platform to create computational replicas of cancer patients using multimodal genomic, imaging and clinical...
Rani and Chugai pair oral‑delivery tech with rare disease antibody: up to $1.08B
Rani Therapeutics struck a deal with Chugai Pharmaceutical to combine Rani’s robotic oral delivery capsule with Chugai’s experimental rare‑disease antibody, a pact valued at up to $1.08 billion....
FDA picks first nine recipients for National Priority Vouchers pilot
The U.S. Food and Drug Administration announced the first nine awardees of the Commissioner’s National Priority Voucher (CNPV) pilot program, which aims to accelerate review for products...
Roche strengthens ADC pipeline: Hansoh license nets $80M upfront, up to $1.45B
Roche struck two deals tied to antibody‑drug conjugates this week: a headline license for Hansoh Pharma’s early‑stage CDH17‑targeting ADC with up to $1.45 billion in downstream payments, and a...
Tumor microbes force cancer quiescence and blunt chemotherapy
Researchers at MD Anderson described a mechanism by which tumor‑infiltrating bacteria, notably Fusobacterium nucleatum, induce quiescence in epithelial cancer cells, enabling immune evasion and...
FDA names nine for priority-review pilot: two-month decisions possible
The U.S. Food and Drug Administration unveiled the first cohort of companies selected for its Commissioner’s National Priority Voucher (CNPV) pilot, a program designed to cut review times for...
Enhertu moves into earlier disease — ESMO data open curative debate
New data presented at ESMO show AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu produced strong benefit when moved into earlier-stage HER2-positive breast cancer, prompting...
Roche’s oral SERD shows broader activity — trial separates it from rivals
Roche reported Phase 3 data showing its oral selective estrogen receptor degrader (SERD) giredestrant reduced risk of progression in ER-positive, HER2-negative breast cancer patients, including...
Grail’s Galleri tightens accuracy — PATHFINDER data shift screening debate
Grail released updated PATHFINDER study data showing improved positive predictive value for its multi-cancer blood test Galleri and announced performance metrics from a large U.S. cohort. The...
Sophia Genetics launches Digital Twins: simulate response across multimodal datasets
Sophia Genetics introduced a Digital Twins module within its Sophia DDM cloud platform to model patient-specific disease trajectories using integrated clinical, genomic, imaging and pathology...
Roche pays $80M upfront for Hansoh ADC — deal worth up to $1.45B
Roche struck a global licensing deal with Hansoh Pharma, paying an $80 million upfront cash fee for rights to an early-stage antibody-drug conjugate targeting CDH17 in colorectal cancer. The...
Rani links with Chugai on oral delivery: pact worth up to $1.08B
Rani Therapeutics announced a strategic collaboration with Chugai to pair Rani’s oral biologic delivery capsule with a Chugai experimental antibody for a rare-disease indication, in a deal valued...
Pelage raises $120M series B to push hair-stem-cell therapy to phase III
Pelage Pharmaceuticals closed a $120 million Series B financing led by ARCH Venture Partners and GV to advance its hair follicle stem cell program PP405 toward Phase III testing. The funds will...